Clinical Trials Logo

Advanced Solid Malignancies clinical trials

View clinical trials related to Advanced Solid Malignancies.

Filter by:

NCT ID: NCT00979563 Completed - Clinical trials for Advanced Solid Malignancies

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies

Oratecan-101
Start date: July 2008
Phase: Phase 1
Study type: Interventional

The main objective of this study is to determine the maximum tolerated dose (MTD) of OratecanTM. Eligible subjects of this study are patients with histologically or cytologically confirmed malignant solid tumor refractory to standard therapy or for which no established therapy exists at the time of study participation.

NCT ID: NCT00979134 Terminated - Cancer Clinical Trials

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Start date: October 21, 2009
Phase: Phase 1
Study type: Interventional

This study is primarily designed to assess the safety and tolerability of AZD4547 at increasing doses in patients with advanced solid malignancies and for whom no standard medication options are available. It also assesses the blood levels and action of AZD4547 in the body over a period of time.

NCT ID: NCT00973076 Completed - Cancer Clinical Trials

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.

NCT ID: NCT00937664 Terminated - Cancer Clinical Trials

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

Start date: July 2009
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.

NCT ID: NCT00879905 Completed - Clinical trials for Advanced Solid Malignancies

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Start date: May 2009
Phase: Phase 1
Study type: Interventional

This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.

NCT ID: NCT00871559 Completed - Clinical trials for Advanced Solid Malignancies

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Start date: June 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of REGN421 (SAR153192) in patients with advanced solid malignancies.

NCT ID: NCT00733031 Terminated - Solid Tumors Clinical Trials

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Start date: August 2008
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD6918 based on the side effects experienced by patients with advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918 will be administered twice daily. Then maximum tolerated doses in combination with either gemcitabine or pemetrexed will also be investigated.

NCT ID: NCT00669097 Completed - Clinical trials for Advanced Solid Malignancies

Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies

Start date: April 2008
Phase: Phase 1
Study type: Interventional

This is a phase l study to examine Absorption, Distribution, Metabolism and Excretion of TKI258. There are 2 cohorts. Cohort 1 (4 patients) will receive single radio-labeled 500mg dose of TKI258 followed after 15 days by daily dosing of 400mg TKI258. Cohort 2 (9 patients) will receive 400mg TKI258.

NCT ID: NCT00637039 Completed - Clinical trials for Advanced Solid Malignancies

Study of AZD8931 in Patients With Advanced Solid Malignancies

Start date: February 2008
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies

NCT ID: NCT00572364 Completed - Clinical trials for Advanced Solid Malignancies

Open Label, Dose Escalation Phase I Study of AZD2281

Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies